PPP2R5B
Basic information
Region (hg38): 11:64917553-64934475
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the PPP2R5B gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 12 | |||||
missense | 31 | 33 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | 2 | |||
non coding | 9 | |||||
Total | 0 | 0 | 33 | 16 | 6 |
Variants in PPP2R5B
This is a list of pathogenic ClinVar variants found in the PPP2R5B region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
11-64925753-C-T | PPP2R5B-related disorder | Uncertain significance (Jan 09, 2023) | ||
11-64925766-C-T | not specified | Uncertain significance (Jul 26, 2024) | ||
11-64925806-A-C | Likely benign (Sep 01, 2024) | |||
11-64925833-C-A | Likely benign (Nov 25, 2023) | |||
11-64925835-G-C | not specified | Uncertain significance (May 20, 2024) | ||
11-64925843-C-T | not specified | Uncertain significance (Oct 20, 2021) | ||
11-64925852-C-T | not specified | Uncertain significance (Dec 22, 2023) | ||
11-64925861-C-T | not specified | Uncertain significance (Jul 30, 2023) | ||
11-64925875-C-A | PPP2R5B-related disorder | Likely benign (Apr 04, 2024) | ||
11-64925902-G-A | Likely benign (Jan 13, 2024) | |||
11-64925902-G-C | not specified | Uncertain significance (Mar 11, 2022) | ||
11-64925917-G-A | Benign/Likely benign (Aug 01, 2024) | |||
11-64926692-G-C | Likely benign (Nov 30, 2021) | |||
11-64926734-C-T | Likely benign (Nov 28, 2023) | |||
11-64926737-G-A | PPP2R5B-related disorder | Likely benign (Apr 01, 2023) | ||
11-64926781-T-C | not specified | Uncertain significance (Nov 03, 2022) | ||
11-64926789-T-A | Uncertain significance (Apr 04, 2022) | |||
11-64926797-C-G | PPP2R5B-related disorder | Likely benign (Apr 04, 2024) | ||
11-64926822-C-T | Uncertain significance (Sep 22, 2023) | |||
11-64926835-A-G | not specified | Uncertain significance (May 18, 2022) | ||
11-64926866-G-A | Likely benign (Aug 05, 2023) | |||
11-64926885-G-A | not specified | Uncertain significance (Dec 27, 2023) | ||
11-64926885-G-C | Uncertain significance (Dec 07, 2023) | |||
11-64927829-C-G | Uncertain significance (Sep 19, 2022) | |||
11-64927831-G-A | Likely benign (Aug 27, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
PPP2R5B | protein_coding | protein_coding | ENST00000164133 | 13 | 16921 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.984 | 0.0158 | 125740 | 0 | 8 | 125748 | 0.0000318 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.46 | 182 | 302 | 0.602 | 0.0000188 | 3219 |
Missense in Polyphen | 70 | 124.49 | 0.56228 | 1262 | ||
Synonymous | 0.363 | 117 | 122 | 0.958 | 0.00000698 | 988 |
Loss of Function | 4.16 | 3 | 25.8 | 0.116 | 0.00000120 | 303 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000181 | 0.000181 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.0000544 | 0.0000544 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000264 | 0.0000264 |
Middle Eastern | 0.0000544 | 0.0000544 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: As the regulatory component of the serine/threonine- protein phosphatase 2A (PP2A) holoenzyme, modulates substrate specificity, subcellular localization, and responsiveness to phosphorylation. The phosphorylated form mediates the interaction between PP2A and AKT1, leading to AKT1 dephosphorylation. {ECO:0000269|PubMed:21329884}.;
- Pathway
- PI3K-Akt signaling pathway - Homo sapiens (human);Dopaminergic synapse - Homo sapiens (human);Oocyte meiosis - Homo sapiens (human);mRNA surveillance pathway - Homo sapiens (human);AMPK signaling pathway - Homo sapiens (human);Adrenergic signaling in cardiomyocytes - Homo sapiens (human);Sphingolipid signaling pathway - Homo sapiens (human);Human papillomavirus infection - Homo sapiens (human);XBP1(S) activates chaperone genes;Focal Adhesion-PI3K-Akt-mTOR-signaling pathway;PI3K-Akt Signaling Pathway;Glycogen Metabolism;Degradation of beta-catenin by the destruction complex;RAF activation;Signaling by WNT;Signal Transduction;GPCR Dopamine D1like receptor;CTLA4 inhibitory signaling;Costimulation by the CD28 family;Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal;Amplification of signal from the kinetochores;Mitotic Spindle Checkpoint;Cell Cycle Checkpoints;Immune System;Adaptive Immune System;insulin Mam;RHO GTPases Activate Formins;Disassembly of the destruction complex and recruitment of AXIN to the membrane;RHO GTPase Effectors;Signaling by Rho GTPases;Hemostasis;Negative regulation of MAPK pathway;RAF/MAP kinase cascade;MAPK1/MAPK3 signaling;MAPK family signaling cascades;PIP3 activates AKT signaling;Beta-catenin phosphorylation cascade;PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling;Negative regulation of the PI3K/AKT network;Mitotic Prometaphase;Separation of Sister Chromatids;Mitotic Anaphase;Mitotic Metaphase and Anaphase;M Phase;Cell Cycle;Resolution of Sister Chromatid Cohesion;Platelet sensitization by LDL;Platelet homeostasis;Cell Cycle, Mitotic;Intracellular signaling by second messengers;TCF dependent signaling in response to WNT;insulin
(Consensus)
Recessive Scores
- pRec
- 0.107
Intolerance Scores
- loftool
- 0.175
- rvis_EVS
- -0.54
- rvis_percentile_EVS
- 20.26
Haploinsufficiency Scores
- pHI
- 0.161
- hipred
- Y
- hipred_score
- 0.785
- ghis
- 0.645
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.946
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Ppp2r5b
- Phenotype
Gene ontology
- Biological process
- protein dephosphorylation;regulation of signaling receptor activity;positive regulation of neuron projection development;regulation of phosphatidylinositol 3-kinase signaling;positive regulation of protein complex assembly;regulation of protein autophosphorylation;IRE1-mediated unfolded protein response;regulation of phosphoprotein phosphatase activity;positive regulation of transcription by RNA polymerase II;regulation of peptidyl-tyrosine phosphorylation;positive regulation of DNA-binding transcription factor activity;positive regulation of neurotrophin TRK receptor signaling pathway;negative regulation of G0 to G1 transition;positive regulation of cell cycle arrest;cellular response to growth factor stimulus
- Cellular component
- protein phosphatase type 2A complex;nucleus;cytoplasm;cytosol
- Molecular function
- protein binding;protein phosphatase regulator activity;protein phosphatase activator activity